Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) dropped 2% during trading on Tuesday . The stock traded as low as $2.36 and last traded at $2.39, with a volume of 396,366 shares changing hands. The stock had previously closed at $2.44.

A number of equities analysts have recently issued reports on BDSI shares. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Tuesday, July 5th. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Janney Montgomery Scott reissued a “hold” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. Finally, Piper Jaffray Cos. reissued a “sell” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and an average target price of $7.00.

The firm has a 50 day moving average price of $2.55 and a 200-day moving average price of $2.72. The stock’s market cap is $128.20 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/biodelivery-sciences-international-inc-bdsi-trading-down-2.html

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The business earned $5 million during the quarter, compared to the consensus estimate of $3.35 million. BioDelivery Sciences International had a negative return on equity of 233.80% and a negative net margin of 109.64%. The company’s revenue for the quarter was up 194.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) earnings per share. On average, equities analysts expect that BioDelivery Sciences International Inc. will post ($1.14) earnings per share for the current year.

In related news, Director William B. Stone sold 16,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the completion of the transaction, the director now directly owns 122,675 shares in the company, valued at $315,274.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.00% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY increased its position in BioDelivery Sciences International by 1.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 32,132 shares of the specialty pharmaceutical company’s stock worth $104,000 after buying an additional 581 shares during the period. Squarepoint Ops LLC increased its position in BioDelivery Sciences International by 22.1% in the first quarter. Squarepoint Ops LLC now owns 41,400 shares of the specialty pharmaceutical company’s stock worth $134,000 after buying an additional 7,500 shares during the period. Alpine Partners VI LLC purchased a new position in BioDelivery Sciences International during the second quarter worth approximately $147,000. Krilogy Financial LLC purchased a new position in BioDelivery Sciences International during the second quarter worth approximately $164,000. Finally, Menta Capital LLC purchased a new position in BioDelivery Sciences International during the second quarter worth approximately $224,000. Institutional investors and hedge funds own 60.12% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.